BioLife Solutions (BLFS)
Supplies preservation media and cell-processing tools for cell and gene therapy workflows.
$37.41
vs last close−0.66 (−1.73%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 33 | 18 | 20 | 31 | −3 | 24 | 25 | 28 | 19 | 28 | 28 |
| Cost of revenue | 22 | 23 | 6 | 7 | 9 | −12 | 8 | 9 | 10 | 6 | 10 | 10 |
| Gross profit | 12 | 9 | 12 | 13 | 22 | 8 | 16 | 16 | 18 | 13 | 17 | 18 |
| 27 | 22 | 16 | 15 | 23 | 7 | 17 | 33 | 18 | 7 | 17 | 17 | |
| Research & development | 5 | 4 | 4 | 2 | 2 | 1 | 2 | 3 | 3 | 0 | 3 | 3 |
| 16 | 18 | 13 | 12 | 15 | 6 | 14 | 14 | 15 | 13 | 15 | 13 | |
| Selling & marketing | 5 | 5 | 2 | 2 | 4 | −1 | 3 | 3 | 3 | 2 | 3 | 3 |
| General & administrative | 13 | 13 | 10 | 9 | 11 | 7 | 12 | 11 | 12 | 11 | 12 | 11 |
| Other expenses | 6 | 1 | −1 | 1 | 6 | 0 | 1 | 16 | 1 | −6 | 0 | 0 |
| Operating income | −9 | −13 | −3 | −1 | −2 | 1 | −1 | −17 | 0 | 6 | 0 | 2 |
| −7 | 0 | 0 | −4 | 0 | 0 | 1 | 1 | 1 | −2 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Interest expense | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Other non-operating income | 0 | −7 | 0 | 0 | 0 | −4 | 0 | −1 | 0 | 2 | 0 | −1 |
| Income before tax | −16 | −13 | −3 | −6 | −2 | 2 | 0 | −16 | 1 | 3 | 1 | 3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −42 |
| Net income from continuing operations | −16 | −13 | −3 | −6 | −2 | 2 | 0 | −16 | 1 | 4 | 1 | 45 |
| Discontinued operations | −13 | 0 | −7 | −15 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −29 | −13 | −10 | −21 | −2 | 12 | 0 | −16 | 1 | 4 | 1 | 45 |
| EPS, basic | −$0.67 | −$0.31 | −$0.22 | −$0.50 | −$0.04 | $0.27 | −$0.01 | −$0.33 | $0.01 | $0.08 | $0.02 | $0.92 |
| EPS, diluted | −$0.67 | −$0.31 | −$0.22 | −$0.50 | −$0.04 | $0.26 | −$0.01 | −$0.33 | $0.01 | $0.08 | $0.02 | $0.91 |
| Weighted average shares, basic | 44 | 44 | 45 | 46 | 46 | 47 | 47 | 48 | 48 | 48 | 48 | 49 |
| Weighted average shares, diluted | 44 | 44 | 45 | 46 | 46 | 48 | 47 | 48 | 49 | 49 | 49 | 49 |
| EBITDA | −25 | −4 | −1 | 1 | 1 | 7 | 0 | −14 | 1 | 5 | 1 | 3 |
| Depreciation & amortization | 4 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | −29 | −6 | −3 | −1 | −1 | 5 | −1 | −16 | 0 | 4 | 0 | 3 |